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Abstract
Objective: To evaluate the clinical impact of chromosomal microarray (CMA) on the management of paediatric patients in
Hong Kong.
Methods: We performed NimbleGen 135k oligonucleotide array on 327 children with intellectual disability (ID)/
developmental delay (DD), autism spectrum disorders (ASD), and/or multiple congenital anomalies (MCAs) in a university-
affiliated paediatric unit from January 2011 to May 2013. The medical records of patients were reviewed in September 2013,
focusing on the pathogenic/likely pathogenic CMA findings and their ‘‘clinical actionability’’ based on established criteria.
Results: Thirty-seven patients were reported to have pathogenic/likely pathogenic results, while 40 had findings of
unknown significance. This gives a detection rate of 11% for clinically significant (pathogenic/likely pathogenic) findings.
The significant findings have prompted clinical actions in 28 out of 37 patients (75.7%), while the findings with unknown
significance have led to further management recommendation in only 1 patient (p,0.001). Nineteen out of the 28
management recommendations are ‘‘evidence-based’’ on either practice guidelines endorsed by a professional society
(n = 9, Level 1) or peer-reviewed publications making medical management recommendation (n = 10, Level 2). CMA results
impact medical management by precipitating referral to a specialist (n = 24); diagnostic testing (n = 25), surveillance of
complications (n = 19), interventional procedure (n = 7), medication (n = 15) or lifestyle modification (n = 12).
Conclusion: The application of CMA in children with ID/DD, ASD, and/or MCAs in Hong Kong results in a diagnostic yield of
,11% for pathogenic/likely pathogenic results. Importantly the yield for clinically actionable results is 8.6%. We advocate
using diagnostic yield of clinically actionable results to evaluate CMA as it provides information of both clinical validity and
clinical utility. Furthermore, it incorporates evidence-based medicine into the practice of genomic medicine. The same
framework can be applied to other genomic testing strategies enabled by next-generation sequencing.
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Introduction
Chromosomal microarray (CMA) has emerged as a major tool
to identify unbalanced chromosomal aberrations in children for its
higher resolution compared to conventional cytogenetics and is
recommended as the first-tier investigation for intellectual
disability (ID)/developmental delay (DD), autism spectrum disor-
ders (ASD) and multiple congenital anomalies (MCAs). [1–9]
Balanced rearrangements and low-level mosaicism are generally
not detectable; however, these are relatively infrequent causes of
abnormal phenotypes in patients (,1%). [2] Large-scale studies in
Asian populations have revealed similar detection rates compared
to studies conducted in Europe and Northern America. [10–13]
While the clinical interpretation of microarray anomalies
remains an ongoing challenge, the impact of CMA results on
clinical management is not well studied. Surveys of physicians
showed changes in management in 70% patients with positive
CMA results [14]. Multiple case reports have demonstrated the
usefulness of CMA in identifying the genetic causes in patients
with unknown diagnoses and in uncovering cancer susceptibility.
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[15–17] In a cohort of 1792 patients with ID, ASD and/or MCAs,
management recommendations were made in 54% patients with
clinically significant CMA results and 34% with findings of
possible significance. [18] Riggs et al. compiled a list of 146
genomic disorders which would be detected by CMA for which
there are published evidence supporting management recommen-
dation and identified that 7% of all cases in the ISCA
(International Standards for Cytogenomic Arrays) Consortium
database are ‘‘clinically actionable’’. [19] In a review based on
46298 cases in the laboratory database, Ellison et al found that
35% of the cases with positive CMA results were established
microdeletion/microduplication syndromes, conditions with in-
creased cancer susceptibility or other actionable conditions
associated with dosage-sensitive genes. [20] Henderson et al.
found that 55% of the positive CMA results prompted clinical
actions in their cohort of 1780 cases. [21]
Despite the growing evidence of its diagnostic yield and cost-
effectiveness [22], CMA has not yet been implemented as a first-
tier diagnostic test for the above mentioned conditions for children
in Hong Kong. The objective of this study is to evaluate the
clinical impact of CMA on the medical management of the
paediatric patients in whom CMA was applied as first-tier clinical
testing in Hong Kong. We study the clinical impact of CMA by
evaluating the detection rate of pathogenic/likely pathogenic
findings and the proportion of these findings that are clinically
actionable, and the level of evidence supporting these recommen-
dations.
Materials and Methods
Patients and Samples
From January 2011, we started to offer CMA to paediatric
patients in 2 university-affiliated hospitals: Queen Mary Hospital
(QMH) and the Duchess of Kent Children’s Hospital (DKCH).
Indications for CMA included unexplained ID/DD, ASD, or
multiple MCAs after review by a clinical geneticist. Clinically
recognizable syndromic conditions, e.g. Down syndrome, were
confirmed by conventional cytogenetic (e.g. karyotype)/molecular
tests (e.g. rapid aneuploidy detection by QF-PCR and fluorescent
in-situ hybridization, FISH) instead of ‘‘first-tiered’’ CMA, and
referred for CMA when conventional investigation showed
negative results. Written informed consent for CMA was obtained
from all parents/legal guardians. Clinicians or geneticists coun-
seled the parents/guardians about the indication for the CMA,
benefits and limitations of the test, methodology, reporting time
and possible outcomes upon recruitment. Patients who had
received prenatal CMA testing or parents who opted not to
receive test result were excluded.
CMA testing and interpretation
For each patient, 3 ml of peripheral blood in EDTA bottle was
sent to Prenatal Diagnostic Laboratory, Tsan Yuk Hospital
(TYH). All samples were tested by NimbleGen CGX-135K arrays
designed by Signature Genomics (Roche NimbleGen, Inc.,
Madison, WI, USA) following manufacturer’s instructions. The
coverage of the array has an average resolution of 140 kb across
the genome and 40 kb or less in regions of clinical relevance. It
evaluates over 245 known genetic syndromes and over 980 gene
regions of functional significance in human development. Data
were analyzed by Genoglyphix software (Signature Genomics,
Spokane, USA). Genomic coordinates were based on genome
build hg18.
Detected copy number variants (CNVs) were systematically
evaluated for its clinical significance by comparing the CNVs to
information in the Signature Genomics’ proprietary Genoglyphix
Chromosome Aberration Database (Signature Genomics, Spo-
kane, WA, USA), internal laboratory database at TYH and public
databases [Database of Genomic Variant (DGV), International
Standards for Cytogenomic Arrays Consortium Database (ISCA),
Children Hospital of Philadelphia database (CHOP), Database of
Chromosomal Imbalance and Phenotype in Humans using
Ensembl Resources (DECIPHER)]. Categorization of CNVs was
based on available phenotypes and comparison of phenotypes with
genes in the region of copy gain or loss. This was done through
searching Online Mendelian Inheritance in Man (OMIM),
PubMed, RefSeq, the University of California Santa Cruz (UCSC)
genome browser. [23] Confirmatory FISH/qPCR/conventional
karyotype was performed as indicated. Parental testing was offered
to aid further interpretation and classification. CNVs were
classified as pathogenic, likely pathogenic, unknown/uncertain
significance, or benign according to the 2011 American College of
Medical Genetics (ACMG) practice guideline. [24] Only patho-
genic and likely pathogenic CNVs are regarded as clinically
significant.
Management actions based on clinically significant CMA
result
We identified 327 patients that fulfilled our inclusion criteria on
whom we have performed CMA from the period January 2011 to
May 2013. Retrospective medical record review was performed in
September 2013 when all the abnormal CMA results had been
disclosed to the patients/families in the post-test genetic counseling
session. We analyzed the detection rate of clinically significant
CMA results (pathogenic or likely pathogenic) and the medical
management recommendations directly based on these findings.
Since the interpretation of CNVs can evolve with new evidence
over a short period of time, we also evaluated CNVs classified as
‘‘benign’’ and ‘‘unknown significance’’ for comparison.
A recommendation for clinical action was defined as any
management recommendations prompted by CMA results
including recurrent surveillance (S), specialist referral/assessment
(R), diagnostic investigation (D) such as laboratory tests, ECG,
diagnostic imaging studies etc., medical/surgical procedure (P),
drug administration (M) (such as indication/contraindication for
drug treatment), lifestyle recommendation (L) and other interven-
tions (O) such as alternative therapies etc. [18,19] Information on
the clinically actionable genomic regions and the level of
supporting evidence (Level 1 to 4) proposed by Riggs et al. [19]
was used to analyze our findings. We did not include genetic
counseling (for advice on reproductive options and/or prenatal
diagnosis), confirmatory karyotype/QF-PCR/FISH, or parental
testing which was done to clarify CNVs inheritance as countable
clinical action.
Statistical Analysis
Unpaired t-test was used for comparing CNVs size between
pathogenic or likely pathogenic group and unknown clinical
significance group. Fisher’s exact tests were used to examine any
potential association between CMA outcome and patients’
characteristics including age group, gender and indications for
CMA. Statistical analysis was carried out using IBM SPSS
Statistics software version 19. A two-tailed p-value of less than
0.05 was treated as statistically significant.
Ethics Statement
Approval was obtained from the Institutional Review Board of
the University of Hong Kong and Hospital Authority of Hong
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Kong West Cluster. The title of the approved study is
‘‘Comparative study in prenatal/postnatal diagnostic detection
using microarray technology and conventional cytogenetic anal-
ysis’’, under the reference number UW10-226. Written informed
consent was obtained from all parents/legal guardians.
Results
Three hundred and twenty seven patients had CMA testing in
the 29 months period and all were included in our analysis. Thirty-
three patients were found to have pathogenic CNVs; 4 with likely
pathogenic CNVs; 40 with CNVs of unknown significance, while
the rest had benign CNVs. The detection rate of clinically
significant CNVs (pathogenic or likely pathogenic) was 11.3% (37/
327). In the group with clinically significant findings, 22 patients
had copy number loss (deletions), 9 had copy number gain
(duplications), and 6 patients had both deletion and duplication.
There were a total of 45 clinical significant CNVs and 6 CNVs of
unknown clinical significance found in these 37 patients. Of the
group with CNVs of unknown clinical significance, 11 were
deletions, 26 were duplications, and 3 were both deletion and
duplication. There were a total of 45 CNVs of unknown clinical
significance in these 40 patients. (See Table 1 for characteristics of
the patients, Table 2 for CNVs types and numbers in clinically
significant CNVs and CNVs with unknown significance group.)
Patients with clinically significant CNVs were younger (age,12
months old, p,0.001, by Fisher’s exact test), more likely to be
female (p,0.001, by Fisher’s exact test) and also more frequently
had MCA/dysmorphism as indications for CMA (p,0.001, by
Fisher’s exact test), compared to others (Table 1). The mean size
of clinical significant CNVs (9.20 Mb64.56 Mb, mean695%
C.I.) was larger than that of CNVs of unknown significance
(0.53 Mb60.19 Mb) (p,0.001, by unpaired t-test). Copy number
loss was found more frequently in clinically significant CNVs than
in CNVs of unknown clinical significance (64.4% compared to
31.1%, p= 0.003, by Fisher’s exact test).
Within the group of patients with clinically significant CNVs,
there were patients with well-known genomic disorders including
1p36 deletion (n= 1), Wolf-Hirschhorn syndrome (n= 2), Cri du
Chat syndrome (n= 2), Klinefelter syndrome (n= 1), 22q11.2
deletion (n= 2), and Williams syndrome (n= 3). CMA was offered
to these patients either because their clinical features did not allow
definitive diagnosis of the condition, or because they were atypical
deletions or duplications that could not be detected by standard
cytogenetic methods e.g. 22q11.2 deletion. [25] A few patients
with interesting clinical/CMA findings in this cohort have been
reported previously. [26–28]
Recommendations for clinical management were made in
75.7% (28 out of 37) patients with significant CNVs (Table 3), and
in 2.5% (1 in 40) patients with unknown significance (see
discussion section for detail of this case) respectively (p,0.001
by Fisher’s exact test). Specific clinical actions for the patients with
significant CNVs include 19 recommendations for surveillance (S),
24 specialist referrals (R), 25 diagnostic tests (D), 7 medical/
surgical procedures (P), 15 recommendations regarding drug
administration (M), 12 recommendations for lifestyle modification
(L). According to the criteria by Riggs et al. [19], in nine of these
patients, recommendations were based on Level 1 evidence, i.e.
from practice guideline endorsed by a professional society; 10 were
based on Level 2 evidence, i.e. from peer-reviewed publication
describing medical management recommendations; 8 were based
on Level 3 evidence, i.e. from peer-reviewed publications not
regarding management but implying potential management based
on clinical judgment; 1 was based on Level 4 evidence, i.e. could
Table 1. Patients’ characteristics and CMA findings.
[A] Number of patients
with Pathogenic or Likely
Pathogenic CNVs (%)
[B] Number of patients with
CNVs of Unknown Clinical
Significance (%)
[C] Number of
patients with
Benign CNVs (%)
[A] vs [B+C] comparison
(by Fisher’s exact test)
Total 37/327 (11.3%) 40/327 (12.2%) 250/327 (76.5%)
Age p,0.001
,12 m 20/37 (54.1%) 4/40 (10.0%) 34/250 (13.6%)
1 – 5 y 10/37 (27.0%) 27/40 (67.5%) 164/250 (65.6%)
6 – 10 y 2/37 (5.4%) 6/40 (15.0%) 28/250 (11.2%)
11 – 18 y 4/37 (10.8%) 2/40 (5.0%) 20/250 (8.0%)
.18 y 1/37 (2.7%) 1/40 (2.5%) 4/250 (1.6%)
Gender p,0.001
Male 15/37 (40.5%) 32/40 (80.0%) 172/250 (68.8%)
Female 22/37 (59.5%) 8/40 (20.0%) 78/250 (31.2%)
Indications (Number of total cases) p,0.001
Neurodevelopmental disorders
(DD/ID/ASD) (215 cases)
9/37 (24.3%) 28/40 (70.0%) 178/250 (71.2%)
9/215 (4.2%)* 28/215 (13.0%)* 178/215 (82.8%)*
MCA/Dysmorphism 6 neurodevelopmental
disorders (105 cases)
26/37 (70.3%) 12/40 (30.0%) 67/250 (26.8%)
26/105 (24.8%)* 12/105 (11.4%)* 67/105 (63.8%)*
Others (7 cases) 2/37 (5.4%) 0/40 (0%) 5/250 (2.0%)
2/7 (28.6%)* 0/7 (0%)* 5/7 (71.4%)*
* = detection rate based on referring indications. Abbreviations: MCA=Multiple Congenital Anomalies; DD=Developmental Delay; ID = Intellectual Disability;
ASD=Autism Spectrum Disorders; m=months old, y = years old.
doi:10.1371/journal.pone.0109629.t001
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be managed symptomatically regardless of underlying diagnosis.
Of the 28 patients with recommendations made based on the
CMA result, 21 of them have findings overlapping with the
clinically actionable genomic regions reported by Riggs et al. in
2013. [19] In the other 7 patients, management recommendations
were made for one patient with Klinefelter syndrome (Level 1
evidence), one with trisomy X syndrome (Level 2 evidence) while
in the rest the recommendations were based on case series/case
reports (Level 3 evidence). The overall diagnostic yield of clinically
actionable abnormal CMA findings is 8.6% (28/327).
Case Illustration
Level 1 evidence for clinical action: 47,XXY/Klinefelter
syndrome (Case 37 in Table 3)
A 3 year old boy presented with speech delay and autistic
features. He was born preterm following a spontaneous mono-
chorionic diamniotic twin pregnancy. CMA showed arr(1-
22,X)62,(Y)61 (confirmed by karyotype). He was referred to the
endocrinology clinic, where he was managed according to existing
protocols for Klinefelter syndrome with other various recommen-
dations (R,D,P,S,M,L). [29,30] His otherwise healthy twin was
also confirmed to have Klinefelter Syndrome. Their mother was
pregnant when the diagnosis of Klinefelter syndrome was disclosed
and parental karyotype was offered due to their anxiety. The
karyotype of their father was normal while that of their mother (30
years old) showed low level mosaicism of 47,XXX[1]/46,XX[29].
Sex chromosome aneuploidy is recognized to be a normal
phenomenon in culture lymphocytes from women of different
ages and specifically it was reported that 4% of women between 23
to 34 years of age can have X chromosome gain. [31] This low
frequency of aneuploid cells does not signify an increased risk of
prenatal diagnosis of sex chromosomal aneuploidy in the fetus and
this was explained to the parents in subsequent session of genetic
counseling.
Level 2 evidence for clinical action: 1p36 deletion (Case 1
in Table 3)
A newborn girl was diagnosed to have Ebstein anomaly. She
developed a generalized seizure shortly after cardiac surgery on
day 3 of life. CMA showed diagnosis of 1p36 microdeletion
syndrome (OMIM #607872). Neurodevelopmental and feeding
assessment (R), eye assessment (S), EEG (D), brain MRI (D), USG
kidney (D), and thyroid function test (S) were recommended. [32]
Thyroxine replacement (M) and antiepileptic therapy (M) were
prescribed subsequently. Parents were provided with extensive
counseling on the prognosis and management of the condition.
The patient had a prolonged hospital stay and died at 20 months
of age after an acute deterioration without identifiable cause.
Level 3 evidence for clinical action: 1q44 deletion (Case 3
in Table 3)
A full term baby with pulmonary atresia, ventricular septal
defect and thyroid agenesis was referred for genetic evaluation at 2
months of age. She had a history of intrauterine growth restriction
and exhibited failure to thrive. CMA showed 1q44 deletion [arr
1q44(241,821,041–247,174,728) 61]. Her clinical features were
consistent with the phenotype associated with 1q44 deletion
(OMIM #612337). Seizures and abnormal corpus callosum are
commonly reported. [33–35] Our patient was recommended to
have brain MRI which showed a hypoplastic corpus callosum.
Upon our recommendation, she was followed by the neurologists
and confirmed to have severe DD. She later developed seizures
and required antiepileptic treatment.
No recommendation for clinical action: submicroscopic
unbalanced translocation (Case 2 in Table 3)
A 24 year-old female being followed in the paediatric clinic was
referred for evaluation of developmental delay and dysmorphic
features. She had a past history of being small for gestational age,
short stature, scoliosis, hypotonia and resolved tremor/head
shaking. All her previous investigations, including brain MRI
(hypoplastic inferior vermis), karyotype, FISH for Williams
syndrome, 7 blood tests and 2 urine tests for metabolic diseases,
spine MRI, nerve conduction velocity/electromyography, Tensi-
lon test, muscle biopsy, were non-diagnostic. CMA showed
terminal 1p36.33p36.32 duplication and terminal 10q26.2q26.3
deletion, suggesting an unbalanced translocation. The unbalanced
translocation was then confirmed by FISH. Patients with 10q26
deletion are reported to share similar features of ID/DD,
dysmorphic features, as well as behavioral problems. [36–38]
Although there was no clinical action prompted in this patient, this
case showed how first-tier CMA testing might have avoided 15
unnecessary investigations (including the invasive muscle biopsy)
and ended the diagnostic odyssey.
Discussion
A growing body of evidence demonstrates the superior
diagnostic yield of CMA compared to conventional karyotype,
and CMA has been endorsed by various professional organizations
as a first-tier investigation for children with unexplained DD/ID/
ASD and/or MCAs. [2,3] However in the States, the evidence has
not been sufficient to support coverage of CMA by many health
insurance providers. The decision of which often depends on the
evidence of whether a test will influence medical management and
result in improvement in health outcome. In Hong Kong where
most medical expenses are publicly funded, similar decisions have
to be made by the government for supporting new testing and
Table 2. CNVs type in patients with clinically significant CNVs and patients with CNVs of unknown clinical significance.
CNVs type Patients with clinically significant CNVs (n =37) Patients with CNVs of unknown clinical significance (n =40)
One deletion 21/37 11/40
Two deletions 1/37 0
One duplication 8/37 24/40
Two duplications 1/37 2/40
Deletion and Duplication 6/37 3/40
doi:10.1371/journal.pone.0109629.t002
The Clinical Impact of Chromosomal Microarray on Paediatric Care in HK
PLOS ONE | www.plosone.org 4 October 2014 | Volume 9 | Issue 10 | e109629
T
a
b
le
3
.
M
an
ag
e
m
e
n
t
re
co
m
m
e
n
d
at
io
n
s
fo
r
cl
in
ic
al
ly
si
g
n
if
ic
an
t
C
N
V
s
an
d
re
co
m
m
e
n
d
at
io
n
ac
co
rd
in
g
to
th
e
le
ve
l
o
f
e
vi
d
e
n
ce
.
C
a
se
n
o
.
A
g
e
/
S
e
x
In
d
ic
a
ti
o
n
G
e
n
o
m
ic
co
o
rd
in
a
te
s
(h
g
1
8
)
o
f
C
N
V
s
C
N
V
si
z
e
a
n
d
ty
p
e
/s
y
n
d
ro
m
e
o
r
lo
cu
s
P
a
re
n
ta
l
T
e
st
in
g
C
li
n
ic
a
l
a
ct
io
n
L
e
v
e
l
o
f
e
v
id
e
n
ce
1
*
1
m
/F
M
C
A
/d
ys
ch
r1
:
8
2
5
,5
1
3
–
6
,4
8
9
,8
1
8
5
.6
M
b
te
rm
in
al
co
p
y
lo
ss
at
1
p
3
6
.3
3
–
p
3
6
.3
1
/1
p
3
6
d
e
le
ti
o
n
D
e
n
o
vo
R
,D
,S
,M
le
ve
l
2
2
*
2
4
y/
F
M
C
A
/d
ys
+D
D
ch
r1
:
8
2
5
,5
1
3
–
3
,9
3
0
,3
7
1
;
ch
r1
0
:
1
2
9
,1
8
8
,0
6
5
–
1
3
5
,2
5
3
,2
4
0
3
.1
M
b
co
p
y
g
ai
n
at
1
p
3
6
.3
3
–
p
3
6
.3
2
an
d
6
M
b
co
p
y
lo
ss
at
1
0
q
2
6
.2
–
q
2
6
.3
/
u
n
b
al
an
ce
d
tr
an
sl
o
ca
ti
o
n
N
n
o
n
o
3
*
2
m
/F
M
C
A
ch
r1
:
2
4
1
,8
2
1
,
0
4
1
–
2
4
7
,1
7
4
,7
2
8
5
.3
M
b
te
rm
in
al
co
p
y
lo
ss
at
1
q
4
4
/1
q
4
4
d
e
le
ti
o
n
N
R
,D
le
ve
l
3
4
*
1
8
y/
M
M
C
A
+D
D
,
cy
to
g
e
n
e
ti
c
d
ia
g
n
o
si
s
ch
r3
:
7
6
,2
7
7
–
8
,7
2
0
,1
7
0
;
ch
r1
0
:
1
0
2
,4
7
4
,0
0
1
–
1
3
5
,2
4
6
,4
0
2
8
.6
M
b
te
rm
in
al
co
p
y
lo
ss
at
3
p
2
6
.3
–
p
2
5
.3
;
3
2
.7
M
b
te
rm
in
al
co
p
y
g
ai
n
at
1
0
q
2
4
.3
1
–
q
2
6
.3
/u
n
b
al
an
ce
d
tr
an
sl
o
ca
ti
o
n
N
n
o
n
o
5
*
3
y/
F
M
C
A
+c
yt
o
g
e
n
e
ti
c
d
ia
g
n
o
si
s
ch
r4
:
3
3
,8
6
0
–
1
5
,6
4
0
,6
1
7
1
5
.6
M
b
co
p
y
lo
ss
at
4
p
1
6
.3
–
p
1
5
.3
2
/W
o
lf
–
H
ir
sc
h
h
o
rn
sy
n
d
ro
m
e
N
R
,D
,P
,M
le
ve
l
2
6
*
4
m
/M
M
C
A
ch
r5
:
1
0
8
,3
6
8
–
1
3
3
,
4
8
5
;
ch
r1
5
:
2
0
,3
7
2
,9
0
1
–
3
7
,6
0
3
,
9
5
5
2
5
.1
kb
co
p
y
lo
ss
(U
C
S)
at
5
p
1
5
.3
3
;
1
7
.2
M
b
co
p
y
lo
ss
at
1
5
q
1
1
.2
–
q
1
4
,
ka
ry
o
ty
p
in
g
sh
o
w
e
d
lo
ss
o
f
ch
ro
m
o
so
m
e
1
5
se
g
m
e
n
t
p
ro
xi
m
al
to
1
5
q
1
5
:
ka
ry
o
ty
p
e
4
5
,X
Y
,d
e
r(
5
)t
(5
;
1
5
)(
p
1
5
.3
;q
1
5
)d
n
,
–
1
5
/E
xp
an
d
e
d
P
ra
d
e
r–
W
ill
i
sy
n
d
ro
m
e
D
e
n
o
vo
R
,D
,S
,M
,L
fo
r
P
W
S;
R
,D
fo
r
1
5
q
1
3
.3
d
e
l
le
ve
l
1
fo
r
P
W
S,
le
ve
l
2
fo
r
1
5
q
1
3
.3
d
e
l
7
*
6
d
/F
M
C
A
ch
r5
:
1
0
8
,4
6
7
–
1
7
,7
2
3
,1
0
7
1
7
.6
M
b
te
rm
in
al
co
p
y
lo
ss
at
5
p
1
5
.3
3
–
p
1
5
.1
/C
ri
d
u
C
h
at
sy
n
d
ro
m
e
D
e
n
o
vo
R
,D
,S
le
ve
l
2
8
*
7
m
/F
M
C
A
ch
r5
:
1
0
8
,4
6
7
–
1
,2
3
7
,5
6
5
;
ch
r5
:
1
,2
5
5
,9
2
9
–
2
7
,7
8
2
,
1
1
9
1
.1
3
M
b
te
rm
in
al
co
p
y
g
ai
n
at
5
p
1
5
.3
3
;
2
6
.5
M
b
co
p
y
lo
ss
at
5
p
1
5
.3
3
–
p
1
4
.1
/C
ri
d
u
C
h
at
sy
n
d
ro
m
e
N
R
,D
,S
le
ve
l
2
9
*
1
0
m
/F
M
C
A
+D
D
+A
SD
ch
r5
:
1
0
8
,4
6
7
–
1
,5
9
7
,3
2
3
;
ch
r1
1
:
1
1
5
,1
9
0
,3
0
2
–
1
3
4
,4
3
4
,1
3
0
1
.5
M
b
te
rm
in
al
co
p
y
lo
ss
at
5
p
1
5
.3
3
;
1
9
.2
M
b
te
rm
in
al
co
p
y
g
ai
n
at
1
1
q
2
3
.2
–
q
2
5
/
u
n
b
al
an
ce
d
m
at
.
tr
an
sl
o
ca
ti
o
n
t(
5
;1
1
)(
p
1
5
.3
;q
2
3
)
M
at
R
,D
,S
le
ve
l
2
1
0
*
2
m
/F
M
C
A
ch
r5
:
5
8
,8
6
0
,9
4
4
–
5
9
,1
2
4
,6
9
1
;
ch
r7
:
7
2
,3
8
2
,8
5
0
–
7
3
,
7
7
6
,2
3
7
2
6
3
.7
kb
co
p
y
lo
ss
(U
C
S)
at
5
q
1
1
.2
–
q
1
2
.1
;
1
.4
M
b
co
p
y
lo
ss
at
7
q
1
1
.2
3
/W
ill
ia
m
s
sy
n
d
ro
m
e
N
R
,D
,S
,M
,L
le
ve
l
1
1
1
‘
3
.1
y/
M
A
SD
ch
r6
:
1
6
2
,5
4
1
,
9
7
7
–
1
6
3
,0
1
5
,8
2
4
4
7
3
kb
co
p
y
g
ai
n
at
6
q
2
6
D
e
n
o
vo
n
o
n
o
1
2
*
9
m
/F
M
C
A
ch
r7
:
7
2
,3
8
2
,8
5
0
-
7
3
,7
7
6
,2
3
7
1
.4
M
b
co
p
y
lo
ss
at
7
q
1
1
.2
3
/W
ill
ia
m
s
sy
n
d
ro
m
e
N
R
,D
,S
,M
,L
le
ve
l
1
1
3
*
6
d
/M
M
C
A
ch
r7
:
7
2
,3
8
2
,8
5
0
–
7
3
,7
7
6
,2
3
7
;
ch
r2
0
:
3
4
,1
1
8
,9
1
7
–
3
4
,1
7
3
,
5
9
2
1
.4
M
b
co
p
y
lo
ss
at
7
q
1
1
.2
3
;
5
4
.6
kb
co
p
y
lo
ss
(U
C
S)
at
2
0
q
1
1
.2
3
/W
ill
ia
m
s
sy
n
d
ro
m
e
N
R
,D
,S
,M
,L
le
ve
l
1
The Clinical Impact of Chromosomal Microarray on Paediatric Care in HK
PLOS ONE | www.plosone.org 5 October 2014 | Volume 9 | Issue 10 | e109629
T
a
b
le
3
.
C
o
n
t.
C
a
se
n
o
.
A
g
e
/
S
e
x
In
d
ic
a
ti
o
n
G
e
n
o
m
ic
co
o
rd
in
a
te
s
(h
g
1
8
)
o
f
C
N
V
s
C
N
V
si
z
e
a
n
d
ty
p
e
/s
y
n
d
ro
m
e
o
r
lo
cu
s
P
a
re
n
ta
l
T
e
st
in
g
C
li
n
ic
a
l
a
ct
io
n
L
e
v
e
l
o
f
e
v
id
e
n
ce
1
4
*
5
y/
M
A
SD
ch
r7
:
1
1
0
,7
6
5
,4
3
2
–
1
1
1
,1
2
4
,4
0
5
;
ch
r1
5
:
8
2
,4
3
3
,2
5
0
–
8
9
,4
2
7
,
2
2
3
3
5
8
.9
kb
co
p
y
lo
ss
(p
at
e
rn
al
)
at
7
q
3
1
.1
;
6
.9
M
b
co
p
y
lo
ss
at
1
5
q
2
5
.2
–
q
2
6
.1
/1
5
q
d
e
le
ti
o
n
D
e
n
o
vo
n
o
n
o
1
5
*
6
y/
F
M
C
A
+D
D
ch
r9
:
1
9
9
,2
5
4
–
1
,5
3
2
,0
8
4
;
ch
r9
:
1
,5
4
4
,6
9
2
–
2
9
,9
8
0
,9
3
5
1
.3
M
b
te
rm
in
al
co
p
y
lo
ss
at
9
p
2
4
.3
;
2
8
.4
M
b
co
p
y
g
ai
n
at
9
p
2
4
.3
–
p
2
1
.1
/
co
m
p
le
x
im
b
al
an
ce
d
9
p
:
ka
ry
o
ty
p
e
4
6
,X
X
,d
e
r(
9
)(
p
2
1
.1
–
.
p
2
4
.3
::p
2
4
.3
–
.
q
te
r)
d
n
D
e
n
o
vo
n
o
n
o
1
6
*
2
m
/F
M
C
A
ch
r9
:
9
5
,9
2
9
,4
0
5
–
9
6
,7
0
8
,9
5
6
;
ch
r2
2
:
4
6
,6
0
0
,3
1
5
–
4
9
,5
2
2
,
6
5
8
7
7
9
.5
kb
co
p
y
g
ai
n
(U
C
S)
at
9
p
2
2
.3
2
;
2
.9
M
b
co
p
y
lo
ss
at
2
2
q
1
3
.3
1
–
q
1
3
.3
3
/r
in
g
ch
r2
2
w
it
h
2
2
q
1
3
m
ic
ro
d
e
le
ti
o
n
(i
n
cl
u
d
in
g
SH
A
N
K
3
)
N
R
,D
,S
,L
le
ve
l
3
1
7
*
4
y/
F
M
C
A
+D
D
ch
r1
0
:
1
2
5
,9
1
1
,5
6
3
–
1
3
5
,2
5
3
,2
4
0
9
.3
M
b
te
rm
in
al
co
p
y
lo
ss
at
1
0
q
2
6
/1
0
q
2
6
d
e
le
ti
o
n
D
e
n
o
vo
D
le
ve
l
3
1
8
*
2
m
/M
M
C
A
ch
r1
6
:
1
4
,9
5
7
,3
0
0
–
1
6
,1
9
5
,4
0
4
1
.2
M
b
co
p
y
lo
ss
at
1
6
p
1
3
.1
1
/1
6
p
1
3
.1
1
m
ic
ro
d
e
le
ti
o
n
N
R
,D
,P
le
ve
l
3
1
9
‘
2
.5
y/
M
A
SD
ch
r1
6
:
1
5
,0
3
3
,2
5
9
–
1
6
,1
9
5
,4
0
4
1
.2
M
b
co
p
y
g
ai
n
at
1
6
p
1
3
.1
1
/1
6
p
1
3
.1
1
d
u
p
lic
at
io
n
M
at
D
le
ve
l
3
2
0
‘
8
y/
M
A
SD
+D
D
ch
r1
6
:
1
5
,0
3
3
,2
5
9
–
1
6
,1
9
5
,4
0
4
1
.2
M
b
co
p
y
g
ai
n
at
1
6
p
1
3
.1
1
/1
6
p
1
3
.1
1
d
u
p
lic
at
io
n
N
D
le
ve
l
3
2
1
*
1
y/
M
A
SD
ch
r1
6
:
2
8
,3
9
5
,9
9
2
–
2
8
,9
5
3
,7
8
5
5
5
8
kb
co
p
y
lo
ss
at
1
6
p
1
1
.2
/1
6
p
1
1
.2
(S
H
2
B
1
g
e
n
e
)
m
ic
ro
d
e
le
ti
o
n
D
e
n
o
vo
R
,S
le
ve
l
2
2
2
*
1
1
y/
M
D
ys
+D
D
ch
r1
6
:
5
4
,4
7
6
,6
4
6
–
5
8
,8
1
6
,9
3
9
4
.3
M
b
co
p
y
lo
ss
at
1
6
q
1
2
.2
–
q
2
1
/1
6
q
1
2
.2
d
e
le
ti
o
n
D
e
n
o
vo
D
le
ve
l
4
2
3
*
1
m
/M
M
C
A
/d
ys
ch
r1
7
:
7
4
0
,2
8
7
–
1
,5
3
0
,7
4
6
7
9
0
kb
co
p
y
g
ai
n
at
1
7
p
1
3
.3
/1
7
p
1
3
.3
d
u
p
lic
at
io
n
N
R
,S
le
ve
l
3
2
4
*
7
m
/M
M
C
A
ch
r1
7
:
2
,5
2
0
,7
0
2
–
3
,6
8
0
,5
8
6
1
.1
6
M
b
co
p
y
lo
ss
at
1
7
p
1
3
.3
–
p
1
3
.2
/1
7
p
1
3
.3
p
1
3
.2
(L
IS
1
in
tr
ag
e
n
ic
d
e
le
ti
o
n
)
D
e
n
o
vo
n
o
n
o
2
5
*
4
m
/F
M
C
A
/d
ys
ch
r1
7
:
2
6
,1
4
0
,6
2
1
–
2
7
,3
4
6
,7
4
4
1
.2
M
b
co
p
y
g
ai
n
at
1
7
q
1
1
.2
/1
7
q
1
1
.2
N
F1
d
u
p
lic
at
io
n
N
R
,S
le
ve
l
3
2
6
*
8
m
/F
M
C
A
ch
r1
7
:
4
3
,8
7
8
,1
5
6
–
4
5
,7
1
9
,3
2
8
;
ch
r1
7
:
6
2
,0
4
7
,2
7
8
–
6
2
,3
7
2
,
3
6
5
1
.8
M
b
co
p
y
lo
ss
at
1
7
q
2
1
.3
2
–
q
2
1
.3
3
;
3
2
5
kb
co
p
y
g
ai
n
(U
C
S)
at
1
7
q
2
4
.2
/1
7
q
2
1
.3
2
–
q
2
1
.3
3
d
e
le
ti
o
n
N
R
,D
,P
,M
,L
le
ve
l
2
2
7
*
2
m
/F
M
C
A
+c
yt
o
g
e
n
e
ti
c
d
ia
g
n
o
si
s
ch
r1
8
:
3
0
,2
7
3
,5
8
5
–
6
2
,9
3
9
,6
7
3
3
2
.6
M
b
co
p
y
g
ai
n
at
1
8
q
1
2
.1
–
q
2
2
.1
/i
n
ve
rt
e
d
d
u
p
lic
at
io
n
1
8
q
1
2
.1
–
q
2
2
.1
O
n
ly
m
o
th
e
r
te
st
e
d
,
n
o
t
m
at
.
n
o
n
o
2
8
*
1
m
/F
M
C
A
ch
r2
2
:
1
7
,2
9
9
,4
6
9
–
1
9
,7
9
0
,6
5
8
2
.5
M
b
co
p
y
lo
ss
at
2
2
q
1
1
.2
1
/2
2
q
1
1
d
e
le
ti
o
n
D
e
n
o
vo
R
,D
,S
,M
,L
le
ve
l
1
2
9
*
3
y/
M
A
SD
ch
r2
2
:
1
7
,2
9
9
,4
6
9
–
1
9
,7
9
0
,6
5
8
2
.5
M
b
co
p
y
lo
ss
at
2
2
q
1
1
.2
1
/2
2
q
1
1
d
e
le
ti
o
n
D
e
n
o
vo
R
,D
,S
,M
,L
le
ve
l
1
The Clinical Impact of Chromosomal Microarray on Paediatric Care in HK
PLOS ONE | www.plosone.org 6 October 2014 | Volume 9 | Issue 10 | e109629
T
a
b
le
3
.
C
o
n
t.
C
a
se
n
o
.
A
g
e
/
S
e
x
In
d
ic
a
ti
o
n
G
e
n
o
m
ic
co
o
rd
in
a
te
s
(h
g
1
8
)
o
f
C
N
V
s
C
N
V
si
z
e
a
n
d
ty
p
e
/s
y
n
d
ro
m
e
o
r
lo
cu
s
P
a
re
n
ta
l
T
e
st
in
g
C
li
n
ic
a
l
a
ct
io
n
L
e
v
e
l
o
f
e
v
id
e
n
ce
3
0
‘
4
.9
y/
M
A
SD
ch
rX
:
2
2
,8
5
7
,4
0
4
–
2
2
,9
8
0
,0
6
9
1
2
2
kb
co
p
y
lo
ss
at
X
p
2
2
.1
1
in
vo
lv
in
g
d
e
le
ti
o
n
o
f
th
e
D
D
X
5
3
g
e
n
e
M
at
n
o
n
o
3
1
*
2
m
/F
M
C
A
,
cy
to
g
e
n
e
ti
c
d
ia
g
n
o
si
s
ch
rX
:
7
1
,0
1
0
,7
1
7
–
1
5
4
,8
8
1
,5
1
4
8
3
.9
M
b
te
rm
in
al
co
p
y
g
ai
n
at
X
q
1
3
.1
–
q
2
8
/f
u
n
ct
io
n
a
l
p
ar
ti
al
m
o
n
o
so
m
y
1
5
an
d
T
ri
so
m
y
X
q
,
ka
ry
o
ty
p
e
4
6
,X
X
,d
e
r(
1
5
)t
(X
;1
5
)(
q
1
3
.1
;p
1
0
)d
n
N
R
,D
,S
,M
,L
le
ve
l
2
3
2
*
1
3
y/
F
o
th
e
r
ch
rX
:
1
0
7
,5
3
9
,6
3
2
–
1
0
7
,7
5
0
,7
7
3
;
ch
rX
:
1
0
7
,7
5
9
,1
6
4
–
1
0
8
,1
8
0
,8
3
7
2
1
1
.1
kb
co
p
y
lo
ss
at
X
q
2
2
.3
;
4
2
1
.6
kb
co
p
y
g
ai
n
at
X
q
2
2
.3
/X
–
lin
ke
d
A
lp
o
rt
p
lu
s
d
if
fu
se
le
io
m
yo
m
at
o
si
s
sy
n
d
ro
m
e
O
n
ly
m
o
th
e
r
te
st
e
d
,
n
o
t
m
at
.
R
,D
,S
,M
le
ve
l
2
3
3
*
9
m
/F
D
ys
+D
D
+
cy
to
g
e
n
e
ti
c
d
ia
g
n
o
si
s
ch
rX
:
1
3
4
,4
5
9
,0
0
7
–
1
3
4
,9
0
1
,9
1
4
;
ch
r4
:
3
3
,8
6
0
–
1
1
,2
9
5
,9
5
9
4
4
2
.9
kb
co
p
y
lo
ss
(U
C
S)
at
X
q
2
6
.3
;
1
1
.2
M
b
te
rm
in
al
co
p
y
lo
ss
at
4
p
1
6
.3
–
p
1
5
.3
3
/W
o
lf
–
H
ir
sc
h
h
o
rn
sy
n
d
ro
m
e
D
e
n
o
vo
R
,D
,P
,M
le
ve
l
2
3
4
*
3
y/
F
A
SD
ch
rX
:
2
1
6
,5
1
9
–
4
,0
3
1
,2
2
0
3
.8
M
b
co
p
y
lo
ss
at
X
p
2
2
.3
3
/X
p
2
2
.3
3
(S
H
O
X
)
d
e
le
ti
o
n
Le´
ri
–
W
e
ill
d
ys
ch
o
n
d
ro
st
e
o
si
s
sy
n
d
ro
m
e
N
R
,D
,P
,S
,M
,L
le
ve
l
1
3
5
*
1
2
y/
F
o
th
e
r,
g
e
n
e
ti
c
d
ia
g
n
o
si
s
ch
rX
:
2
1
6
,5
1
9
–
3
9
,3
1
5
,0
1
3
3
9
.1
M
b
te
rm
in
al
co
p
y
lo
ss
at
X
p
2
2
.3
3
–
p
1
1
.4
/X
p
2
2
.3
3
p
1
1
.4
D
e
n
o
vo
R
,D
,P
,S
,M
,L
le
ve
l
1
3
6
*
9
m
/F
M
C
A
+D
D
ch
rX
:
3
6
9
,
1
9
0
–
8
8
6
,6
5
3
;
1
8
:
3
,4
0
4
,5
6
9
–
3
,8
8
6
,1
4
7
5
1
7
.4
kb
co
p
y
g
ai
n
(m
at
e
rn
al
)
at
X
q
2
8
;
4
8
1
.5
kb
co
p
y
g
ai
n
at
1
8
p
1
1
.3
1
/1
8
p
1
1
.3
1
d
u
p
lic
at
io
n
M
at
n
o
n
o
3
7
*
3
y/
M
A
SD
ch
rX
4
7
,X
X
Y
(g
ai
n
o
f
ch
rX
)/
K
lin
e
fe
lt
e
r
sy
n
d
ro
m
e
In
co
n
cl
u
si
ve
;
K
ar
yo
ty
p
e
o
f
m
o
th
e
r:
m
o
s
4
7
,X
X
X
[1
]/
4
6
,X
X
[2
9
]
R
,D
,P
,S
,M
,L
le
ve
l
1
A
b
b
re
vi
at
io
n
s:
M
C
A
=
M
u
lt
ip
le
C
o
n
g
e
n
it
al
A
n
o
m
al
ie
s;
D
D
=
D
e
ve
lo
p
m
e
n
ta
l
D
e
la
y;
A
SD
=
A
u
ti
sm
Sp
e
ct
ru
m
D
is
o
rd
e
rs
;
D
ys
=
D
ys
m
o
rp
h
is
m
;
U
C
S
=
U
n
ce
rt
ai
n
C
lin
ic
al
Si
g
n
if
ic
an
ce
.
A
b
b
re
vi
at
io
n
s:
S
=
Su
rv
e
ill
an
ce
;
R
=
sp
e
ci
al
is
t
R
e
fe
rr
al
/a
ss
e
ss
m
e
n
t;
D
=
D
ia
g
n
o
st
ic
te
st
in
g
;
P
=
m
e
d
ic
al
/s
u
rg
ic
al
P
ro
ce
d
u
re
;
M
=
M
e
d
ic
at
io
n
ad
m
in
is
tr
at
io
n
;
L
=
Li
fe
st
yl
e
re
co
m
m
e
n
d
at
io
n
;
O
=
O
th
e
r
in
te
rv
e
n
ti
o
n
s.
*
=
p
at
h
o
g
e
n
ic
C
N
V
s,
‘
=
lik
e
ly
p
at
h
o
g
e
n
ic
C
N
V
s.
N
=
n
o
t
te
st
e
d
;
M
at
=
m
at
e
rn
al
in
h
e
ri
ta
n
ce
;
P
at
=
p
at
e
rn
al
in
h
e
ri
ta
n
ce
.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
1
0
9
6
2
9
.t
0
0
3
The Clinical Impact of Chromosomal Microarray on Paediatric Care in HK
PLOS ONE | www.plosone.org 7 October 2014 | Volume 9 | Issue 10 | e109629
therefore it is also our interest to study whether a genetic test can
significantly affect clinical management and patient outcome.
To evaluate the degree to which CMA can impact clinical
management of our patient population, we retrospectively
reviewed the medical records of 327 patients tested in a single
laboratory and managed in a single paediatric unit (2 teaching
hospitals) over a 29-month period. We included only patients in
whom the CMA results had been disclosed and management
recommendations have been suggested in a post-test genetic
counseling session. We had full access to the medical records of all
patients and the latest recruited patient had at least 3-month
follow-up period for the evaluation of outcome after the
recommendation. It was noted that parental testing rate was
56.8% in the 37 patients with significant CMA results, due to
either parental refusal.
Compared to 4 previous studies on clinical utility of CMAs [18–
21], we found a detection rate of 8.6% for clinically actionable
CNVs, which was comparable if not slightly higher than the
reported number of 3.6%,7% (Table 4). There are significant
differences in the design in previous studies and we have adopted
the approach used by Riggs et al. [19] We grouped the
recommendations into various categories (S, R, D, P, M, L, O)
and linked them to the current level of evidence. This standardized
approach allows better comparison with other studies and re-
evaluation of our own finding with new evidence after a certain
period of time. [39]
We observed a good correlation between the clinical signifi-
cance and the clinical actionability of the CMA findings. Clinical
management changes were recommended in 75.7% of patients
with clinically significant CNVs; in 2.5% of patients with CNVs of
unknown significance and in 0% with benign findings respectively.
The clinically significant findings are larger in size and were more
likely to be deletions than duplications. Interestingly, in those with
clinically significant CNVs, management recommendations were
made in 22/26 patients (84.6%) with MCA/dysmorphism as an
indication for CMA, compared to 4/9 patients (44%) in those with
neurodevelopmental disorders only. This lower clinical action-
ability rate for CNVs found in patients with isolated neurodevel-
opmental disorders was also observed in previous studies. [18,21]
Young age was associated with clinical significant CNVs in our
study, which was also observed in the study of Coulter et al (2011).
[18]
Only 1 investigation was ordered in 1 patient with CNV of
unknown significance, referred for non-syndromic ASD. The
recommendation (an ECG) was based on the finding of the same
20p12.3 duplication in a single case report on a patient with
familial Wolf-Parkinson-White syndrome. [40] Parents agreed for
ECG on the child because the non-invasive nature of the
investigation and the availability of potential treatment if WPW
was identified. In this patient, the ECG was normal. Similarly we
have made a level 4 recommendation (brain MRI) for another
patient with DD, epilepsy and a 16p12 deletion based on positive
Table 4. Comparison of clinically actionable abnormal CMA findings in published studies.
Study
(published
year)
Coulter et al
(2011) Ellison et al (2012) Riggs et al (2014) Henderson et al (2014) Our study
Study design Retrospective
review of medical
records
Retrospective laboratory database
review (Signature Genomics)
Retrospective laboratory
database review (ISCA)
Retrospective review of
electronic medical
records
Retrospective review of
medical records
Number of
subjects
1,792 46,298 28,256 1,780 327 (first-tiered testing and
with specific indications)
Study period 1 y (2009–2010) 7.5 y (2004–2011) As in March 2012 3 y (2009–2012) 29m (2010–2013)
CMA platforms
used
Not specified Multiple BAC-based and oligo-arrays.
(only those with oligo-arrays
counted to evaluate clinical
actionability)
Multiple platforms (not
specified)
2 high resolution SNP
array platforms
NimbleGen 135k
oligonucleotide array
Definition of
clinically
actionable
results
Findings that
prompt specialist
referral, imaging,
diagnostic test
or medication
prescription.
1. Established microdeletion/
microduplication syndromes; 2.
Conditions with increased cancer
susceptibility; 3. Other actionable
conditions associated with dosage-
sensitive genes.
Conditions diagnosable by
CMA for which referral,
diagnostic testing, surgical/
interventional procedure,
surveillance, medical and
lifestyle changes would be
recommended. The
recommendations were
stratified according to the
level of evidence.
Findings that prompt
recommendations of
further action such as
pharmacologic treatment,
cancer-related screening,
contraindications,
additional evaluation or
referrals.
Criteria by Riggs et al.
Diagnostic yield
of significant
results
235/1,792
(13.0%)
15.4% for the oligo-array (based
on previous study from the
same group)
4,125/28,256 (14.6%) 227/1,780 (12.7%) 37/327 (11.0%)
Clinical
actionability in
those with
significant CMA
results (%)
34.0–54.0% 35.0% 46.0% (66.0% for deletion
cases and 11.0% for
duplication cases)
54.7% (42.1% for
patients referred for
isolated
neurodevelopmental
disorders)
75.7% (44.0% for patients
referred for isolated
neurodevelopmental
disorders)
Clinically
actionability in
the whole
cohort (%)
3.6% 5.4% 7.0% 5.4% 8.6%
doi:10.1371/journal.pone.0109629.t004
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finding of bilateral frontoparietal polymicrogyria (BFPP) in a
patient reported with a similar deletion. [41] In our patient, brain
MRI did not show BFPP. This illustrates that with our study
design we are able to evaluate not only the recommendations we
made based on the CMA findings but the actual clinical outcomes
of patients. This will be important especially for CNVs with
clinical actions based on low level of evidence.
There are multiple advantages of reaching a genetic diagnosis in
patients. First of all, making a diagnosis allows estimation of
recurrence risk and informed decisions about future pregnancies
for the parents. As illustrated by case 37 (with Level 1 evidence),
the clinical utility of CMA in the proband can extend beyond the
affected individuals and familial testing can reveal diagnosis in a
sibling (normal development but with Klinefelter syndrome) with
less obvious clinical manifestations. Secondly, for some like patient
2, a diagnosis of submicroscopic unbalanced translocation helps to
end the 24 years of diagnostic odyssey. If the test is being offered as
first-tier testing in a similar patient at the current time, it may help
to avoid a lot of unnecessary investigations including the more
invasive ones. The direct benefits to clinical management have
been demonstrated by previous studies. [18–21] Our study was
able to confirm that a significant CMA finding influenced medical
management in 75% of our patients. Although our study involves
a smaller number of patients, we were able to study at least the
short-term direct clinical outcomes in our patients who have
received recommendations based on their CMA findings. Future
goals will be the long-term study of the impact on clinical
outcomes for a larger cohort of patients with significant CMA
findings and how the changing interpretation of CMA over time
may change the clinical management of patients with different
categories of findings. We advocate the use of diagnostic yield of
clinically actionable results in the evaluation of CMA testing as this
allows the clinicians to consider both clinical validity and clinical
utility of CMA under the ACCE framework [42–47] and it
provides a link between the practice of medical genetics and
evidence-based medicine.
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